Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing 210001, China.
Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, China.
Nucl Med Biol. 2019 Jul-Aug;74-75:19-24. doi: 10.1016/j.nucmedbio.2019.08.002. Epub 2019 Aug 16.
Glucagon-like peptide-1 receptor (GLP-1R) is a kind of G protein coupled receptor which regulates the insulin secretion and serves as potential target in the diagnosis of functional pancreas neuroendocrine tumor. The aim of this study was to evaluate the feasibility of GLP-1R targeted tracer [Ga]Ga-NOTA-MAL-Cys-exendin-4 in the detection of insulinoma.
NOTA-MAL-Cys-exendin-4 was synthesized and then radiolabeled with gallium-68 in iQS® Ga-68 Fluidic Labeling Module. The in vitro binding affinity and cell uptake studies were evaluated in INS-1 cells. The in vivo micro-PET/CT imaging and biodistribution studies were performed on INS-1 xenograft tumor models.
[Ga]Ga-NOTA-MAL-Cys-exendin-4 can be efficiently radiolabelled with a yield of about 85% (non-decay corrected) and radiochemical purity of >95% with a favorable stability. The molar activity was at least 145.5 GBq/μmol. The affinity (IC50) for [Ga]Ga-NOTA-MAL-Cys-exendin-4 was 12.99 ± 0.81 nM. Micro-PET/CT images showed intense tumor uptake with good contrast to background. Biodistribution study showed the predominant uptake was in the kidney, followed by pancreas, and the liver and spleen just showed mild uptake in the blood-pool phase with rapid clearance. At 1 h post- injection, the tumor to blood, muscle and pancreas ratios were 30.64, 40.21 and 6.46, respectively. Blocking studies showed significantly decreased tumor uptake, which further confirmed binding affinity of [Ga]Ga-NOTA-MAL-Cys-exendin-4 to GLP-1R.
[Ga]Ga-NOTA-MAL-Cys-exendin-4 was easily synthesized with high yield, favorable biodistribution and high affinity to islet tumor cell, making the tracer may have great potential in the detection of GLP-1R positive tumor such as an insulinoma.
评估 GLP-1R 靶向示踪剂[Ga]Ga-NOTA-MAL-Cys-exendin-4 用于检测胰岛素瘤的可行性。
合成 NOTA-MAL-Cys-exendin-4,然后在 iQS® Ga-68 流体标记模块中用镓-68 标记。在 INS-1 细胞中评估其体外结合亲和力和细胞摄取研究。在 INS-1 异种移植肿瘤模型上进行体内 micro-PET/CT 成像和生物分布研究。
[Ga]Ga-NOTA-MAL-Cys-exendin-4 可有效标记,产率约为 85%(未校正衰变),放射化学纯度>95%,稳定性良好。摩尔活性至少为 145.5GBq/μmol。[Ga]Ga-NOTA-MAL-Cys-exendin-4 的亲和力(IC50)为 12.99±0.81nM。micro-PET/CT 图像显示肿瘤摄取强烈,与背景对比度良好。生物分布研究表明,主要摄取部位是肾脏,其次是胰腺,肝脏和脾脏在血池期仅显示轻度摄取,清除迅速。在注射后 1 小时,肿瘤与血液、肌肉和胰腺的比值分别为 30.64、40.21 和 6.46。阻断研究显示肿瘤摄取明显减少,进一步证实了[Ga]Ga-NOTA-MAL-Cys-exendin-4 与 GLP-1R 的结合亲和力。
[Ga]Ga-NOTA-MAL-Cys-exendin-4 易于合成,产率高,生物分布良好,对胰岛细胞瘤细胞具有高亲和力,使示踪剂在检测 GLP-1R 阳性肿瘤(如胰岛素瘤)方面具有很大的潜力。